LataMed AI Corp. (OTC: LMED) announced that development of its mobile healthcare application has entered its final stage, with the company completing testing, optimization, and deployment preparations ahead of planned availability through the Apple App Store and Google Play. Management expects the application to be submitted for distribution and, subject to platform review, become available in the coming weeks. This transition from development to public availability is a significant milestone for the company as it seeks to establish a mobile access point to its digital healthcare ecosystem.
The application is designed to serve as a primary mobile interface for users to access supported healthcare services, digital tools, and additional functionality. The company's development team is focused on final technical testing, interface optimization, and platform compatibility reviews. Once live, the app is expected to provide a scalable foundation for introducing patient-facing tools, healthcare-provider interaction, digital communications, medical and wellness information, and healthcare-service coordination.
Mobile accessibility is particularly important in Latin America, where smartphones are a primary means of accessing digital services for many individuals. By offering the app through both major app marketplaces, LataMed AI aims to provide a direct and accessible way for users to interact with its healthcare ecosystem. This move aligns with the company's broader strategy to connect patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and other stakeholders within a more integrated digital healthcare environment.
The company is also advancing its artificial intelligence-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its healthcare technology strategy. The mobile infrastructure is intended to serve as an additional pathway for users and healthcare professionals to interact with these components, subject to continued development and regulatory approvals.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI. Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes." He added, "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools."
The anticipated release represents a step in moving LataMed AI's technology from development into user-facing digital healthcare infrastructure. Following the initial launch, the company plans to evaluate additional functionality, platform integrations, and user-facing tools for future versions. The company expects to provide updates on submission, availability, and functionality as milestones are completed.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
